Literature DB >> 21463797

Portal vein resection in management of hilar cholangiocarcinoma.

Alan W Hemming1, Kristin Mekeel, Ajai Khanna, Angeles Baquerizo, Robin D Kim.   

Abstract

BACKGROUND: Vascular reconstruction along with major liver resection in the setting of liver dysfunction caused by biliary obstruction can be associated with increased risk. The purpose of this report is to assess the role of portal vein resection and reconstruction in the surgical management of hilar cholangiocarcinoma. STUDY
DESIGN: Ninety-five patients with hilar cholangiocarcinoma who underwent resection between 1999 and 2010 were reviewed. Liver resections performed along with biliary resection included 84 trisegmentectomies (63 right, 21 left) and 11 lobectomies (8 left, 3 right). Thirteen patients also had simultaneous pancreaticoduodenectomy performed. Forty-two patients underwent portal vein resection and reconstruction. Five patients required reconstruction of the hepatic artery. Preoperative portal vein embolization was used in 38 patients.
RESULTS: Patients undergoing resection had a 5% mortality rate, with an overall morbidity rate of 36%. Patients who underwent portal vein resection had perioperative mortality and morbidity similar to those who did not have portal vein resection. Median survival was 38 months (95% CI, 29-51 months), with a 5-year survival rate of 43%. There was no difference in long-term survival between those patients who had portal vein resection and those that did not. Negative margins were achieved in 84% of cases and were associated with improved survival (p < 0.01). Five-year survival rate in patients undergoing R0 resection was 50%. Patients with positive lymph nodes appeared to have a worse 5-year survival rate than patients with node-negative status (23% versus 49%); however, only negative margin status was associated with improved survival by multivariate analysis.
CONCLUSIONS: Surgical resection of hilar cholangiocarcinoma that requires resection of the portal vein can be performed safely and should not be a contraindication to resection.
Copyright © 2011 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21463797     DOI: 10.1016/j.jamcollsurg.2010.12.028

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  36 in total

1.  Principles of surgical resection in hilar cholangiocarcinoma.

Authors:  Emilio Ramos
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

Review 2.  Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma.

Authors:  Saleh Abbas; Charbel Sandroussi
Journal:  HPB (Oxford)       Date:  2013-01-08       Impact factor: 3.647

3.  Improved surgical outcomes for hilar cholangiocarcinoma: changes in surgical procedures and related outcomes based on 40 years of experience at a single institution.

Authors:  Ryota Higuchi; Takehiro Ota; Takehisa Yazawa; Hideki Kajiyama; Tatsuo Araida; Toru Furukawa; Tatsuya Yoshikawa; Ken Takasaki; Masakazu Yamamoto
Journal:  Surg Today       Date:  2015-02-05       Impact factor: 2.549

4.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

Review 5.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

6.  En bloc resection of the hepatoduodenal ligament for advanced biliary malignancy.

Authors:  Yuji Kaneoka; Atsuyuki Maeda; Masatoshi Isogai
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

Review 7.  Assessing resectability in cholangiocarcinoma.

Authors:  Tsuyoshi Sano; Yasuhiro Shimizu; Yoshiki Senda; Taira Kinoshita; Yuji Nimura
Journal:  Hepat Oncol       Date:  2013-12-20

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  Surgical management trends for cholangiocarcinoma in the USA 1998-2009.

Authors:  Jamie E Anderson; Alan W Hemming; David C Chang; Mark A Talamini; Kristin L Mekeel
Journal:  J Gastrointest Surg       Date:  2012-07-31       Impact factor: 3.452

Review 10.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.